We are live on ! Find out more
CRSP icon

CRISPR Therapeutics
CRSP

35 hedge funds and large institutions have $211M invested in CRISPR Therapeutics in 2017 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 9

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

35% more funds holding

Funds holding: 26 → 35 (+9)

7% more capital invested

Capital invested by funds: $198M → $211M (+$13M)

0.41% less ownership

Funds ownership: 24.7% → 24.29% (-0.41%)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
35
Holders Change
+9
Holders Change %
+34.62%
% of All Funds
0.87%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
18
Increased
5
Reduced
3
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
CS
Credit Suisse
Switzerland
+$1.57M
2
PC
Paulson & Co
New York
+$991K
3
Morgan Stanley
Morgan Stanley
New York
+$328K
4
Deutsche Bank
Deutsche Bank
Germany
+$135K
5
IWM
IHT Wealth Management
Illinois
+$109K

Top Sellers

1
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$4.29M
2
JCG
JHL Capital Group
Illinois
-$1.22M
3
LCM
Laurion Capital Management
New York
-$527K
4
CCP
Clough Capital Partners
Massachusetts
-$273K
5
Millennium Management
Millennium Management
New York
-$241K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
26
UBS Group
Switzerland
$12K -$68.2K -3,472 -86%
MFW
27
Mosaic Family Wealth
Missouri
$11K +$9.72K +495 New
IP
28
Intellectus Partners
California
$9K +$1.96K +100 +31%
CFA
29
Carroll Financial Associates
North Carolina
$9K +$8.84K +450 New
AG
30
Advisor Group
Arizona
$7K +$5.89K +300 New
CCM
31
Cribstone Capital Management
Maine
$2K – – –
ASN
32
Advisory Services Network
Georgia
$2K +$1.96K +100 New
Citigroup
33
Citigroup
New York
$2K +$1.96K +100 New
LTFS
34
Ladenburg Thalmann Financial Services
Florida
$2K +$1.96K +100 New
WIM
35
Westside Investment Management
California
$1.99K +$1.96K +100 New
US Bancorp
36
US Bancorp
Minnesota
$1K +$766 +39 New
Lord, Abbett & Co
37
Lord, Abbett & Co
New Jersey
– -$4.29M -211,700 Closed
JCG
38
JHL Capital Group
Illinois
– -$1.22M -60,000 Closed
LCM
39
Laurion Capital Management
New York
– -$527K -26,000 Closed
Millennium Management
40
Millennium Management
New York
– -$241K -11,913 Closed
SIC
41
Salem Investment Counselors
North Carolina
– -$13K -650 Closed
TRCT
42
Tower Research Capital (TRC)
New York
– -$10K -479 Closed
ECM
43
Elgethun Capital Management
South Dakota
– -$6K -300 Closed
TWMP
44
Taylor Wealth Management Partners
Massachusetts
– -$1K -50 Closed
1
2

CRSP Hedge Fund Activity: Q1 2017 in Review

35 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q1 2017, worth a combined $211M — up 6.6% from $198M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new CRSP positions and 9 closed out — a net gain of 9 holders — while 5 added to existing stakes and 3 trimmed.

The largest buyer was Credit Suisse, opening a new position worth an estimated $1.57M. The largest seller was Lord, Abbett & Co, exiting entirely with an estimated $4.29M sold.

  • 35 institutional investors held CRISPR Therapeutics (CRSP) as of Q1 2017, up from 26 in Q4 2016.
  • Funds reported $211M of CRISPR Therapeutics stock for Q1 2017, up 6.6% quarter-over-quarter.
  • 18 funds opened new CRISPR Therapeutics positions in Q1 2017 and 9 closed out, a net change of +9 holders.
  • The largest CRISPR Therapeutics buyer in Q1 2017 was Credit Suisse, an estimated $1.57M added.
  • The largest CRISPR Therapeutics seller in Q1 2017 was Lord, Abbett & Co, an estimated $4.29M sold.

Based on aggregated 13F filings for Q1 2017.